


# ACIP COVID-19 Vaccines Work Group

Dr. Matthew F. Daley, Work Group Chair

September 1, 2022




[cdc.gov/coronavirus](https://cdc.gov/coronavirus)

# Global impact of the first year of COVID-19 vaccinations:

## Mathematical model of transmission and infection based on official reported COVID-19 deaths, 185 countries, December 2020—December 2021

- COVID-19 vaccinations are estimated to have prevented **13.7-15.9** million deaths
- This represents an estimated **63% reduction in** total COVID deaths globally



# Novavax COVID-19 vaccine:

## Updates on use of the protein subunit vaccine platform

- Novavax COVID-19 vaccine is now recommended as a two dose primary series vaccination for people ages **12** years and older
- **670,000** doses have been distributed across all US states and territories
- **3.2 million** doses have been purchased by the US government
- As of August 25<sup>th</sup>, 2022:
  - **14,559** doses have been administered
  - **2,591** people have completed a two dose primary series

# ACIP COVID-19 Work Group Meeting Review: August 2022

## Reviewed extensive data regarding to bivalent boosters and context:

- Data from multiple clinical trials of bivalent boosters, including those with an Omicron component, demonstrating **safety and immunogenicity in >1700 adults** both with and without prior SARS-CoV-2 infection
  - **>1400** individuals received a bivalent vaccine with the **Omicron** component specifically
- Antigenic cartography and immunologic implications of SARS-CoV-2 variants
- Modeling of pandemic outcomes in varied scenarios, demonstrating potential impact of new variants and varying vaccine/booster coverage
- Rare events of myocarditis after COVID-19 vaccination
- Epidemiology of COVID-19 disease and variants, including the currently dominant **Omicron BA 4/5** variant

**Engaged in broad discussions regarding use of bivalent boosters in people of all age groups currently recommended to receive a booster**

# Agenda: Morning of Thursday September 1<sup>st</sup>, 2022

- **Epidemiology of COVID-19 & SARS-CoV-2 variants** Dr. Scobie (CDC)
- **Immunology of SARS-CoV-2 variants** Dr. Thornburg (CDC)
- **Updates to COVID-19 vaccine effectiveness** Dr. Link-Gelles (CDC)
- **Updates to COVID-19 vaccine safety** Dr. Shimabukuro (CDC)

*Break*

**PUBLIC COMMENT**

# Agenda: Afternoon of Thursday September 1<sup>st</sup>, 2022

- **Moderna bivalent COVID-19 vaccine** Dr. Das (Moderna)
- **Pfizer-BioNTech bivalent COVID-19 vaccine** Dr. Gruber (Pfizer)
- Break*
- **Evidence to recommendations framework:** Dr. Oliver (CDC)  
**Bivalent COVID-19 booster doses**
- **Clinical considerations update** Dr. Hall (CDC), Dr. Twentyman (CDC)
- **Discussion**

## VOTE:

**Moderna COVID-19 vaccine, Bivalent, in individuals ages 18 years and older**

**Pfizer-BioNTech COVID-19 vaccine, Bivalent, in individuals ages 12 years and older**

# Work Group members

## ACIP members

- Matthew Daley (chair)
- Beth Bell
- Grace Lee
- Keipp Talbot
- Oliver Brooks

## Ex-officio/government members

- FDA: Doran Fink, Rachel Zhang, Lucia Lee
- NIH: Chris Roberts
- IHS: Uzo Chukwuma
- DOD: Bryan Schumacher
- CMS: Jeff Kelman
- BARDA: Christine Oshansky
- HHS: David Kim

## CDC Leads

- Sara Oliver
- Evelyn Twentyman

## Liaisons

- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- ADS: Emily Kahn
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett, Paul Cieslak, Christine Hahn
- IDSA: Jeff Duchin (primary)

## Liaisons, cont’d


- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis (primary), Kelsey Young (alternate)
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Patricia Whitley-Williams
- SHEA: Marci Drees

## Consultants

- Ed Belongia
- Kathy Kinlaw
- Dayna Matthew
- Kathleen Neuzil
- Stanley Perlman
- Peter Szilagyi
- Jose Romero
- Hank Bernstein

# CDC participants

- Sarah Meyer
- Elisha Hall
- Megan Wallace
- Danielle Moulia
- Lauren Roper
- Hannah Rosenblum
- Katherine Fleming-Dutra
- Monica Godfrey
- Susan Goldstein
- Mary Chamberland
- Stephen Hadler
- Valerie Morelli
- JoEllen Wolicki
- Melinda Wharton
- Jessica MacNeil
- Amanda Cohn
- Tamara Pilishvili
- Ruth Link-Gelles
- Heather Scobie
- Natalie Thornburg
- Tom Shimabukuro
- John Su
- Julianne Gee
- Karen Broder
- Naomi Tepper
- LeAnne Fox
- Rebecca Greco Kone
- Rita Helfand
- Jefferson Jones
- Yvonne Bolen
- Meg Freedman
- Katherine Grusich
- Kristen Nordlund
- Amanda Dudley
- Sierra Scarbrough
- Joy Hsu
- Tara Anderson
- Amy Rubis
- Roodly Archer
- Andrew Kroger
- Lauri Markowitz
- Erin Kennedy
- Ryan Wiegand
- Patricia Yu
- Yon Yu



For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

# Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

